Cardiff University | Prifysgol Caerdydd ORCA
Online Research @ Cardiff 
WelshClear Cookie - decide language by browser settings

Our experience on Actovegin, is it cutting edge?

Lee, Paul, Rattenberry, A., Connelly, S. and Nokes, Leonard Derek Martin 2011. Our experience on Actovegin, is it cutting edge? International Journal of Sports Medicine 32 (4) , pp. 237-241. 10.1055/s-0030-1269862

Full text not available from this repository.

Abstract

Muscle injuries are one of the most common sport related injuries, their incidence varying from 30-55% in all sports injuries. They account for the loss of 90 training days and 15 matches per club per season in elite football (soccer). In recent years, the use of Actovegin® in sports medicine has caused a lot of controversy in many sports disciplines. Although it is unlikely for this deproteinised substance to have oxygen-enhancing capacity, there is an anecdotal belief that Actovegin® can increase an athlete's performance. Actovegin® is produced by Nycomed Austria GmbH and has been used by doctors across Europe, China and Russia for over 60 years. Nevertheless, very little is known regarding the effects of Actovegin on muscle injuries. This article reviews the current evidence on Actovegin®, its legal status with sports governing bodies and its potential role in sport injuries. We will also report our experience with this drug in treating muscle injuries. In this pilot study, players in the Actovegin treatment group were able to return to play 8 days earlier (95% CI −1.249 to −14.7510) compared to physiotherapy alone (p=0.033). No adverse reactions were recorded in any of the participants.

Item Type: Article
Date Type: Publication
Status: Published
Schools: Engineering
Subjects: R Medicine > RM Therapeutics. Pharmacology
R Medicine > RS Pharmacy and materia medica
Uncontrolled Keywords: Actovegin; muscle injuries; doping
Publisher: Georg Thieme Verlag
ISSN: 0172-4622
Last Modified: 20 Oct 2017 17:15
URI: http://orca.cf.ac.uk/id/eprint/14032

Citation Data

Cited 24 times in Google Scholar. View in Google Scholar

Cited 27 times in Scopus. View in Scopus. Powered By Scopus® Data

Actions (repository staff only)

Edit Item Edit Item